Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $38.47 Average Target Price from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has received an average recommendation of “Moderate Buy” from the nineteen research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and three have issued a strong buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $38.4706.

A number of analysts have recently commented on DYN shares. Lifesci Capital upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 14th. Oppenheimer raised Dyne Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $11.00 to $40.00 in a research report on Wednesday, December 10th. Wall Street Zen downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Wednesday, October 8th. Finally, Tudor Pickering set a $23.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, December 9th.

Dyne Therapeutics Stock Down 2.7%

Shares of NASDAQ:DYN opened at $17.77 on Friday. The firm has a 50 day simple moving average of $19.89 and a 200-day simple moving average of $15.25. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $25.00. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $2.54 billion, a PE ratio of -4.86 and a beta of 1.32.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05. On average, equities analysts predict that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC purchased a new stake in Dyne Therapeutics during the 1st quarter valued at approximately $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after purchasing an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Dyne Therapeutics by 58.2% during the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after purchasing an additional 366,183 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of Dyne Therapeutics during the first quarter worth $157,000. Finally, Rhumbline Advisers grew its position in Dyne Therapeutics by 4.2% in the 1st quarter. Rhumbline Advisers now owns 133,627 shares of the company’s stock valued at $1,398,000 after buying an additional 5,383 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.